laboratoires B2A

What laboratoires B2A does

Laboratoires B2A (legal entity LBM B2A) is a private French medical biology laboratory group operating as a SELAS (Société d'Exercice Libéral) under the direction of Franck Schickele. Founded in 2012 and headquartered in Brumath, Alsace, the group runs over 60 laboratory sites across eastern France — spanning Alsace (Haut-Rhin, Bas-Rhin), Lorraine (Vosges, Moselle), and Franche-Comté (Belfort area) — under the Les Biologistes Indépendants brand network. Its core offering is routine and specialized clinical biology testing (hematology, biochemistry, hemostasis, immunology, serology, allergology, hormonology, bacteriology, parasitology, mycology, genetic testing) supported by standard clinical analyzers, with additional services including blood tests without prescription (bilans sans ordonnance), free IST screening, the urea breath test (Helikit), spermogram, and chronic kidney disease screening. Patient-facing channels include walk-in sites, home sampling, a secure online results portal (resultats.B2A.fr, mykali-b2a.mesanalyses.fr) integrated with the French Dossier Médical Partagé (DMP) via the national health identifier (INS), Doctolib scheduling at select sites, and an analysis guide hosted on ubilab.io. Specialized sub-brands cover forensic laboratory expertise (B2A Expertise Judiciaire) and a dedicated innovation unit (B2A Innovation), and the group maintains clinical-research activity registered on the French Health Data Hub under CNIL MR-004 methodology, with all health data hosted on HDS-certified infrastructure.

Revenue is generated transactionally through medical biology testing billed primarily to the French Assurance Maladie scheme with tiers-payant (third-party payment) and complementary mutuelles, supplemented by direct patient pay for tests outside the insured nomenclature (e.g., bilans sans ordonnance). Pricing is regulated by the Sécurité sociale reimbursement schedule; IST screening is 100% covered for under-26s and reimbursed at standard rates for others. Customer segments are horizontally distributed: individual patients (walk-in, home-sampling), prescribing physicians receiving validated results, and hospitals/medical establishments using the network as an outsourced lab and second-opinion provider. Geographic footprint is single-country (France) and concentrated entirely in the Grand Est region, with no disclosed parent company, private equity sponsor, or public listing.

Name

laboratoires B2A

Legal name

LBM B2A

Website

https://b2a.fr

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

251–500 employees

Short description

Laboratoires B2A is a private French SELAS operating 60+ independent medical biology laboratory sites across eastern France (Alsace, Lorraine, Franche-Comté, Moselle), providing routine and specialized clinical testing reimbursed by Assurance Maladie, with sub-brands for forensic expertise and innovation.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

akta.pro secondary industries

Hematology & Coagulation Laboratories (HLAFAMAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery) (HLACAMAL)

Keywords

• Medical biology testing
• Clinical laboratory services
• Diagnostic blood analysis
• STI screening services
• Forensic laboratory expertise

Headquarters

HQ city

Brumath

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Laboratory Testing Services: B2A generates revenue through medical biology testing services billed to the French social security system (Assurance Maladie) and complementary health insurers (mutuelles). Standard testing is covered under the national health insurance scheme with third-party payment (tiers-payant), reducing patient out-of-pocket costs. Direct payment options exist for patients exercising right of opposition to standard data processing.
2. Patient Self-Pay Testing: Revenue from tests not covered or partially covered by insurance, including blood tests without prescription (bilans sanguins sans ordonnance) and certain specialized analyses. Patients pay upfront and seek reimbursement from their insurer.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

Laboratoires B2A operates a multi-site network of independent medical biology laboratories that perform clinical diagnostic analyses (blood tests, urine analysis, hematology, biochemistry, immunology, serology, allergology, hemostasis, hormonology, bacteriology, parasitology, mycology, genetic testing, STI screening, spermogram, urea breath test). Services are delivered across 60+ laboratory sites in eastern France with secure digital result delivery and, for selected tests, access without prescription and/or free of charge.

Product overview

Laboratoires B2A is a network of independent medical biology laboratories providing comprehensive clinical diagnostic services. The company operates over 60 laboratory locations across eastern France, offering a unified platform of services including blood tests, specialized diagnostic analyses (hemostasis, immunology, serology, genetics, bacteriology), online result delivery, and specialized tests such as IST screening and breath tests. The group is organized around core medical biology services, the B2A Innovation division for technological advancement, and judicial expertise services. Patients access results through dedicated online portals (resultats.B2A.fr and mykali-b2a.mesanalyses.fr) and a comprehensive analysis guide available through the ubilab.io platform.

Differentiator

Problem solved

Functional benefit

Brands

• B2A Innovation: Innovation division of the B2A group focusing on medical biology innovations.
• B2A Expertise Judiciaire

Products and services

• Medical Biology Laboratory Services Comprehensive clinical diagnostic analyses (blood tests, urine analysis, hematology, biochemistry, hemostasis, immunology, serology, allergology, hormonology, bacteriology, parasitology, mycology, genetic testing) performed at 60+ laboratory sites across Alsace, Lorraine, Vosges, Franche-Comté and Moselle, with medically validated results delivered securely to patients and prescribers.
• Blood Tests Without Prescription (Bilans sanguins sans ordonnance) Self-initiated blood testing service available without a doctor's prescription, designed for basic preventive health assessments with confidentiality and simplicity, billed directly to the patient.
• STI Screening (Dépistage des IST) Sexual-transmitted-infection screening available without prescription or appointment, covered by Assurance Maladie at standard rates for over-26s and at 100% for under-26s, supporting no-friction preventive screening.
• Spermogram Specialized semen analysis service used for male fertility assessment and reproductive health evaluation, performed within the medical biology offering.
• Urea Breath Test (Helikit) Non-invasive 13C-urea breath test for the detection of Helicobacter pylori gastric infection, using Helikit and Helicobacter Test INFAI kits distributed through the laboratory and partner pharmacies.
• Chronic Kidney Disease Screening Preventive screening for chronic kidney disease including blood creatinine testing and urinary albumin/creatinine measurements, made freely available during the Semaine Nationale du Rein national awareness week.
• SCORE2 Cardiovascular Risk Evaluation Preventive cardiovascular risk screening using the European SCORE2 index to evaluate 10-year cardiovascular disease risk, targeted at adults aged 40–69 without prior cardiovascular disease, diabetes, or kidney disease, delivered free at participating B2A laboratories.
• Home Sampling Service (Prélèvement à domicile) At-home biological sampling service for patients with mobility limitations or disabilities, arranged by contacting a B2A laboratory directly, bringing standard medical biology testing into the patient's home.
• B2A Expertise Judiciaire (Forensic Expertise) Forensic and judicial medical-biology expertise services delivered by the B2A group under its dedicated Expertise Judiciaire sub-brand, supporting legal and judicial proceedings requiring specialized biological analyses.

Quantifiable outcome

• Results typically available same day for most standard tests
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Société Française de CardiologiecoreStrategic or Co-development Partner · 26 March 2026Partnership with the French Cardiology Society for cardiovascular risk screening campaigns. B2A participated in the March 2026 SCORE2 cardiovascular risk evaluation initiative organized in partnership with the Société Française de Cardiologie and Alliance du Cœur.
• Alliance du CœurcoreStrategic or Co-development Partner · 26 March 2026Partnership with Alliance du Cœur (heart health association) for cardiovascular risk screening campaigns. Joint initiative in March 2026 for SCORE2 cardiovascular risk assessment at B2A laboratories.
• Les Biologistes IndépendantscoreStrategic or Co-development PartnerB2A is a member of the Les Biologistes Indépendants network, an independent biologists association. This partnership provides brand identity as an independent laboratory group, shared standards and best practices, and collaborative support among independent medical biology laboratories across France.
• CNIL (Commission Nationale de l'Informatique et des Libertés)minorOthersB2A conducts clinical research under CNIL MR-004 methodology, a reference methodology for low-risk research studies that allows processing of health data without explicit consent under specific conditions.
• Section 4 (Web Agency)minorOthersDigital agency responsible for website development and content management. Located at 14 rue Boulay de la Meurthe, 88000 Épinal.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Biogroup: Biogroup is a major French medical biology group operating more than 900 sites across France, providing routine and specialized testing under similar reimbursement and tiers-payant structures as B2A. It competes directly for patients, biologists, and acquisition targets in eastern France.
• Cerba Healthcare: Cerba Healthcare is a leading French and European specialty/reference laboratory group offering routine and esoteric testing with hospital and physician clients. It competes with B2A for specialized test referrals and physician relationships in eastern France.
• Inovie: Inovie is one of France's largest independent medical biology networks, operating hundreds of laboratories nationwide with a similar SELAS structure, multi-specialty testing portfolio, and direct-to-patient service model. It is the most direct large-scale competitive analog to B2A's regional roll-up strategy.
• Synlab: Synlab is one of Europe's largest medical diagnostics providers with a significant French footprint in routine clinical biology and specialty testing. Its scale and pan-European procurement platform make it a key competitor for talent and pricing in the French market.
• Unilabs: Unilabs operates clinical laboratories and imaging centers across France and Europe, offering medical biology services comparable to B2A's core portfolio. It competes on geographic proximity and physician relationships in overlapping French regions.
• Eurofins Genoma Paris (formerly Genoma): Eurofins operates clinical diagnostics laboratories in France through its Genoma and related brands, covering genetics, biochemistry, and specialty testing. It competes with B2A on specialized referrals and serves overlapping physician and hospital customers.

Others

• Doctolib: Doctolib is the dominant French health appointment booking platform that B2A already integrates with for patient scheduling. It is a key ecosystem participant that channels patient demand to labs and physicians and increasingly offers online prescription and result services.
• Doctipharma: Doctipharma is a French online pharmacy that distributes health products and increasingly laboratory test kits. It represents an adjacent channel for at-home sample collection kits, paralleling B2A's pharmacy distribution of Helikit tests.

Direct peers

• Eurofins Biomnis: Eurofins Biomnis is a major French specialty/reference laboratory focused on esoteric testing, serving hospital and physician clients nationwide. It is comparable to B2A's specialty and second-opinion testing capability and competes for complex referral work from B2A's physician network.

Emerging players

• Les Biologistes Indépendants: Les Biologistes Indépendants is a national network of independent French medical biology laboratories of which B2A is itself a member. It is comparable as a peer network sharing brand identity, best practices, and referral pathways across independent regional lab groups.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks2 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/laboratoires-b2a

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about laboratoires B2A